TABLE 2.
Summary of the clinical efficacies of sotorasib and adagrasib.
| Sotorasib | Adagrasib | |
|---|---|---|
| CodeBreaK100 | KRYSTAL-1 | |
| N of patients | 126 | 116 |
| Primary endpoint | ORR | ORR |
| ORR (95% CI) (%) | 37.1 (28.6–46.2) | 43 (33.5–52.6) |
| DOR (95% CI) (month) | 11.1 (6.9–NE) | 8.5 (6.2–13.8) |
| DCR (95% CI) (%) | 80.6 (72.6–87.2) | 80 (70.8–86.5) |
| PFS (95% CI) (month) | 6.6 (5.1–8.2) | 6.5 (4.7–8.4) |
| OS (95% CI) (month) | 12.5 (10.0–NE) | 12.6 (9.2–19.2) |
| Follow-up (month) | 15.3 | 12.9 |
| Brain metastasis, n (%) | 26 (20.6) | 24 (21) |
| Intracranial ORR, DCR (%) | 33, 85 | 12.5, 88 |
| PD rate (%) | 16.1 | 5 |
| Dose reduction/suspension (%) | 22.3 | Reduction: 52; suspension: 61 |
ORR, objective response rate; DOR, duration of response; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; CI, confidence interval; NE, not evaluated; PD, progressive disease.